Current status of multiple sclerosis therapy in Germany: A national survey

European Journal of Neurology

Volumn 6, Issue 1, 1999, Pages 35-38

  Heesen, Christoph ^a   Hauer, Sabine ^a   Hadji Abdolrahim, Bijan ^a   Berenbeck, Christine ^a   Buhmann, Carsten ^a   Emskötter, Thomas ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Azathioprine; Immunomodulation; Interferon 1B; Multiple sclerosis; Therapeutic standards

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; IMMUNOMODULATING AGENT; METHOTREXATE; STEROID;

ARTICLE; CATHETERIZATION; CHRONIC DISEASE; DRUG USE; GERMANY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; STANDARD;

EID: 0033026031     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1999.610035.x     Document Type: Article

References (21)

1. Barnes D, Hughes RAC, Morris RW, Wade-Jones SO, Brown P, Britton T, et al. (1997). Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349:902-906.
2. Beck RW, the Optic Neuritis Study Group (1993). The effect of corticosteroids for acute optic neuritis and the subsequent development of multiple sclerosis. New Engl J Med 329:1764-1769.
3. Cavazzuti M, Merelli E, Tassone G, Luciano M (1997). Lesion load quantification in serial MR of multiple sclerosis patients in azathioprine treatment - a retrospective study. Eur Neurol 38:284-290.
4. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, et al. (1997). Therapeutic effect of mitoxantrone combined with methylpredisolone in multiple sclerosis: a randomised multicenter study of active disaese using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118.
5. European Study Group on interferon β-1b in secondary progressive multiple sclerosis (1998). Placebo-controlled multicenter randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497.
6. Goodkin DE, Rudick RA, Vander Burg Medendorp S, Daughtry MM, Van Dyke C (1995). Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30-40.
7. Hartung HP, Gonsette R, MIMS Study Group (1998). Mitoxantrone in progessive multiple sclerosis: a placebo-controlled, randomized, observer-blind European phase III multicentre study -clinical results. Multiple Sclerosis 4 (Suppl.):325.
8. Hughes RAC, Sharrack B (1996). More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry 61:239-241.
9. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, the Multiple Sclerosis Collaborative Research Group (1996). Interferon beta-1A for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294.
10. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP (1995). Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results for a phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1268-1276.
11. Knutson E, Martensson A, Gransberg L (1982). Antiparetic and antispastic effects induced by tizanidine in patients with spastic paraparesis. J Neurol Sci 5:187-204.
12. Likosky WH, Fireman B, Elmore R, Eno G, Gale KM Broiwne-Goode G, Ikeda K (1991). Intense immuno-suppression in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 44: 828-832.
13. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS (1996). Management of patients recieving interferon beta 1b for multiple sclerosis: report of a consensus conference. Neurology 46:12-18.
14. Millefiorni E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M (1997). A randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153-159.
15. Palace J, Rothwell P (1997). New treatments and azathioprine in multiple sclerosis. Lancet 350:261.
16. PRISMS Study Group (1998). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing remitting multiple sclerosis. Lancet 352:1498-1504.
17. Shapiro RT (1994). Symptom management in multiple sclerosis. Neurology 36:S123-129.
18. Snow, BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990). Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 28:512-515.
19. The Interferon beta Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995). Interferon-beta 1B in the treatment of MS. Final outcome of the randomized controlled trial. Neurology 45:1277-1285.
20. Weiner HL, Mackin GA, Orar CJ, Hafler DA, Dawson DM, LaPierre Y, the North Eastern Cooperative Multiple Sclerosis Treatment Group (1993). Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeastern Cooperative Multiple Sclerosis Trial Group. Neurology 43:910-918.
21. Yudkin PL, Ellsion GA, Ghezzi A, Goodkin DE, Hughes RAC, McPherson K (1991), Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051-1055.